Rafferty Asset Management
BBIO icon

Rafferty Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Rafferty Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
40,953
-22,227
-35% -$1.56M 0.01% 541
2026
Q1 		$4.69M Sell
63,180
-16,838
-21% -$1.22M 0.02% 400
2025
Q4 		$6.12M Sell
80,018
-71,972
-47% -$4.72M 0.02% 373
2025
Q3 		$7.89M Sell
151,990
-44,792
-23% -$2.18M 0.03% 331
2025
Q2 		$8.5M Sell
196,782
-5,346
-3% -$194K 0.03% 301
2025
Q1 		$6.99M Sell
202,128
-48,114
-19% -$1.62M 0.03% 312
2024
Q4 		$6.87M Buy
250,242
+6,911
+3% +$179K 0.02% 349
2024
Q3 		$6.2M Sell
243,331
-28,276
-10% -$742K 0.02% 368
2024
Q2 		$6.88M Sell
271,607
-44,835
-14% -$1.23M 0.03% 346
2024
Q1 		$9.78M Buy
316,442
+40,369
+15% +$1.37M 0.04% 272
2023
Q4 		$11.1M Sell
276,073
-37,309
-12% -$1.12M 0.05% 247
2023
Q3 		$8.26M Sell
313,382
-205,864
-40% -$5.84M 0.05% 277
2023
Q2 		$8.93M Buy
519,246
+177,966
+52% +$2.68M 0.05% 232
2023
Q1 		$5.66M Sell
341,280
-377,989
-53% -$4.41M 0.04% 360
2022
Q4 		$5.48M Buy
719,269
+128,529
+22% +$1.23M 0.05% 358
2022
Q3 		$5.87M Buy
590,740
+137,660
+30% +$1.43M 0.06% 298
2022
Q2 		$4.11M Sell
453,080
-170,122
-27% -$1.42M 0.04% 317
2022
Q1 		$6.33M Buy
623,202
+477,498
+328% +$4.9M 0.04% 312
2021
Q4 		$2.43M Buy
145,704
+83,823
+135% +$3.55M 0.01% 594
2021
Q3 		$2.9M Buy
61,881
+21,078
+52% +$1.13M 0.02% 496
2021
Q2 		$2.49M Sell
40,803
-6,147
-13% -$351K 0.02% 606
2021
Q1 		$2.89M Buy
46,950
+31,754
+209% +$2.08M 0.02% 517
2020
Q4 		$1.08M Sell
15,196
-29,059
-66% -$1.4M 0.01% 481
2020
Q3 		$1.66M Buy
44,255
+10,946
+33% +$344K 0.02% 472
2020
Q2 		$1.09M Buy
+33,309
New +$1.01M 0.02% 519
2020
Q1 		– Sell
-19,248
Closed -$675K – 618
2019
Q4 		$675K Buy
+19,248
New +$534K 0.01% 633

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rafferty Asset Management's BBIO Position: Q2 2026 in Review

Rafferty Asset Management reduced its BridgeBio Pharma (BBIO) stake by 35% in Q2 2026, selling an estimated $1.56M and leaving 40,953 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #541.

Rafferty Asset Management first reported a position in BBIO in Q4 2019 and has held it in 26 quarters since. The position peaked at $11.1M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Rafferty Asset Management held 40,953 shares of BridgeBio Pharma worth $3.05M as of Q2 2026.
  • Rafferty Asset Management sold 22,227 BridgeBio Pharma shares in Q2 2026, an estimated $1.56M.
  • BridgeBio Pharma made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #541 holding.
  • Rafferty Asset Management first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 26 quarters since.
  • Rafferty Asset Management's BridgeBio Pharma position peaked at $11.1M in Q4 2023.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.